In an amicus brief filed in the United States District Court for the Eastern District of Pennsylvania, AAM urged the Court to reject exclusionary contracting and bundling practices that threaten to foreclose or delay biosimilar competition. AAM’s brief helped to explain the need for robust biosimilar competition, the costs and burdens of developing biosimilars, and how such conduct (e.g., bundling other drugs to receive exclusive contracts for originator biologics), if allowed to continue, will result in higher prices and reduced incentives for biosimilar manufacturers to continue to incur the substantial risks entailed in developing and marketing biosimilars.
